Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

82.61 -1.45 (-1.72%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
72 73 Next >
Sanofi Soars as Dupixent Sales Near €5 Billion Amidst Intensifying Trump Drug Pricing Negotiations
Paris, France – October 24, 2025 – Pharmaceutical giant Sanofi (EURONEXT: SAN, NASDAQ: SNY) saw its shares climb today following the announcement of stellar third-quarter 2025 financial results,... 
Via MarketMinute
Topics Government World Trade
3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years
Via MarketBeat
Eccogene Eyes Hong Kong IPO With Experimental Weight-Loss Drug, AstraZeneca Partnership
 
Via Benzinga
Topics Initial Public Offering
Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence
San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the... 
Via MarketMinute
Danaher Corporation Poised for Growth as Q3 2025 Earnings Spark Optimism
Washington D.C., October 22, 2025 – Danaher Corporation (NYSE: DHR) is currently experiencing a wave of positive sentiment, with its stock price widely expected to rise following a robust third-quarter... 
Via MarketMinute
Peering Into AstraZeneca PLC's Recent Short Interest
 
Via Benzinga
AstraZeneca’s Enhertu Achieves Record Response Rate In Phase 3 Trial For Early Breast Cancer
Via Stocktwits
DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option
From AstraZeneca
Via Business Wire
AstraZeneca Reportedly Nears Drug Pricing Deal With President Trump
Via Stocktwits
ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial
From AstraZeneca
Via Business Wire
AstraZeneca, In A Buy Zone, Makes A Big Breast Cancer Splash
AstraZeneca's Enhertu could help some breast cancer patients avoid surgery, according to a study unveiled Saturday at ESMO. 
Via Investor's Business Daily
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial
From AstraZeneca
Via Business Wire
TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps
From AstraZeneca
Via Business Wire
Invo Fertility Stock Is Plunging After White House Announcement
INVO Fertility Inc (NASDAQ:IVF) shares are trading lower on Thursday as investors book profits following White House announcements aimed at making fertility treatments more affordable and accessible. 
Via Benzinga
IMFINZI® (durvalumab) regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial
From AstraZeneca
Via Business Wire
IMFINZI® (durvalumab)-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
From AstraZeneca
Via Business Wire
UK Finance Minister Seeks More Pharma Investment In Exchange For Higher Drug Prices: Report
UK finance minister Rachel Reeves told reporters that the country needs to be an attractive place for pharma, including in terms of pricing. 
Via Benzinga
Merck's Keytruda Plus Chemo Regimen Shows Overall Survival Benefit In Recurrent Ovarian Cancer Patients
Merck's KEYNOTE-B96 trial shows Keytruda with chemotherapy improves survival in platinum-resistant recurrent ovarian cancer with a consistent safety profile. 
Via Benzinga
2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades
These companies are investing heavily into their pipelines and the payoff for long-term investors can be substantial. 
Via The Motley Fool
Eli Lilly's Oral Weight Loss Drug Shows Superiority Over Two Approved Drugs
Orforglipron meets key endpoints in Phase 3 trials, showing A1C reduction, weight loss, and cardiovascular benefits for type 2 diabetes. 
Via Benzinga
AstraZeneca Unveils Expanded Facility In Texas Aimed At Doubling Production Of Hyperkalemia Drug
The facility in Coppell, which employs more than 250 people, is the sole global manufacturing facility for the company’s Lokelma. 
Via Stocktwits
AstraZeneca unveils expanded manufacturing facility in Texas
From AstraZeneca
Via Business Wire
AstraZeneca PLC (NASDAQ:AZN): A Caviar Cruise Quality Investment
Discover AstraZeneca, a top-quality stock with strong growth, high ROIC, and robust cash flow. A prime candidate for long-term investors seeking durable competitive advantages. 
Via Chartmill
Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential
Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at least $5 billion. 
Via Benzinga
Absci's AI Revolution: A New Era for Drug Discovery or a Rocky Road Ahead?
Absci (NASDAQ: ABSI), a pioneer in AI-driven drug discovery, is making significant strides with its "Integrated Drug Creation™ Platform," promising to revolutionize how new medicines are brought to... 
Via MarketMinute
Topics Artificial Intelligence
AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO
From AstraZeneca
Via Business Wire
Trump Plans AstraZeneca Deal To Cut Drug Prices For Low-Income Americans
Trump to announce new deal with AstraZeneca to lower prescription drug costs for Americans using most-favored-nation pricing model. 
Via Benzinga
Topics Government
UK Weighs 25% Rise In Drug Prices As Pharma Giants Pause Investments
UK ministers consider raising NHS drug spending by up to 25% amid pharma investment delays and pressure from US pricing policies. 
Via Benzinga
Pfizer (NYSE:PFE) Marks 348th Consecutive Dividend Payment: A Pillar of Stability Amidst Transformation
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE:PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
Pfizer's 348th Consecutive Dividend: A Beacon of Stability Amidst Industry Headwinds
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE: PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of... 
Via MarketMinute
Topics Economy Intellectual Property Retirement
< Previous 1 2 3 4 5 6 7 8 9
...
72 73 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.